Bachem Holding AG Stock

Equities

BANB

CH1176493729

Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:31:30 2024-04-26 am EDT 5-day change 1st Jan Change
81.1 CHF +2.53% Intraday chart for Bachem Holding AG +3.12% +24.77%
Sales 2024 * 620M 678M Sales 2025 * 811M 887M Capitalization 6.08B 6.65B
Net income 2024 * 127M 139M Net income 2025 * 160M 175M EV / Sales 2024 * 9.7 x
Net cash position 2024 * 64.89M 70.96M Net Debt 2025 * 74.85M 81.84M EV / Sales 2025 * 7.59 x
P/E ratio 2024 *
50.6 x
P/E ratio 2025 *
38.4 x
Employees 2,006
Yield 2024 *
1.06%
Yield 2025 *
1.15%
Free-Float 94.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.53%
1 week+3.12%
Current month-6.13%
1 month-4.64%
3 months+39.59%
6 months+29.45%
Current year+24.77%
More quotes
1 week
77.50
Extreme 77.5
81.55
1 month
76.35
Extreme 76.35
86.50
Current year
53.95
Extreme 53.95
86.50
1 year
53.95
Extreme 53.95
105.60
3 years
49.90
Extreme 49.9
171.00
5 years
24.44
Extreme 24.44
171.00
10 years
8.31
Extreme 8.31
171.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 18-12-31
Director of Finance/CFO 47 21-01-31
Chief Tech/Sci/R&D Officer - 02-12-31
Members of the board TitleAgeSince
Director/Board Member 82 -
Chairman 68 12-04-24
Director/Board Member 51 11-04-12
More insiders
Date Price Change Volume
24-04-26 81.1 +1.50% 41,122
24-04-25 79.9 -1.30% 42,809
24-04-24 80.95 -0.25% 47,904
24-04-23 81.15 +3.51% 49,975
24-04-22 78.4 -0.32% 56,515

Delayed Quote Swiss Exchange, April 26, 2024 at 11:31 am EDT

More quotes
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
6
Last Close Price
81.1 CHF
Average target price
70.8 CHF
Spread / Average Target
-12.70%
Consensus